Cargando…
Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids
BACKGROUND: A recent systematic review, which used the GRADE methodology, concluded that there is strong evidence for two gene-diet associations related to omega-3 and plasma triglyceride (TG) responses. Systematic reviews can be used to inform the development of clinical practice guidelines (CPGs)....
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883048/ https://www.ncbi.nlm.nih.gov/pubmed/35237638 http://dx.doi.org/10.3389/fnut.2021.768474 |
_version_ | 1784659842313486336 |
---|---|
author | Keathley, Justine Garneau, Véronique Marcil, Valérie Mutch, David M. Robitaille, Julie Rudkowska, Iwona Sofian, Gabriela Desroches, Sophie Vohl, Marie-Claude |
author_facet | Keathley, Justine Garneau, Véronique Marcil, Valérie Mutch, David M. Robitaille, Julie Rudkowska, Iwona Sofian, Gabriela Desroches, Sophie Vohl, Marie-Claude |
author_sort | Keathley, Justine |
collection | PubMed |
description | BACKGROUND: A recent systematic review, which used the GRADE methodology, concluded that there is strong evidence for two gene-diet associations related to omega-3 and plasma triglyceride (TG) responses. Systematic reviews can be used to inform the development of clinical practice guidelines (CPGs). OBJECTIVE: To provide guidance for clinical practice related to genetic testing for evaluating responsiveness to dietary/supplemental omega-3s and their impact on plasma lipids/lipoproteins/apolipoproteins. DESIGN: Using the results of the abovementioned systematic review, the first CPGs in nutrigenetics were developed using the established GRADE methodology and AGREE II approach. RESULTS: Three clinical practice recommendations were developed. Most gene-diet associations identified in the literature lack adequate scientific and clinical validity to warrant consideration for implementing in a practice setting. However, two gene-diet associations with strong evidence (GRADE quality: moderate and high) can be considered for implementation into clinical practice in certain cases: male APOE-E4 carriers (rs429358, rs7412) and TG changes in response to the omega-3 fatty acids eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) as well as a 31-SNP nutrigenetic risk score and TG changes in response to EPA+DHA among adults with overweight/obesity. Ethical and regulatory implications must be considered when providing APOE nutrigenetic tests given the well-established link between APOE genetic variation and Alzheimer's Disease. CONCLUSION: Most of the evidence in this area is not ready for implementation into clinical practice primarily due to low scientific validity (low quality of evidence). However, the first CPGs in nutrigenetics have been developed for two nutrigenetic associations with strong scientific validity, related to dietary/supplemental omega-3 and TG responses. |
format | Online Article Text |
id | pubmed-8883048 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88830482022-03-01 Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids Keathley, Justine Garneau, Véronique Marcil, Valérie Mutch, David M. Robitaille, Julie Rudkowska, Iwona Sofian, Gabriela Desroches, Sophie Vohl, Marie-Claude Front Nutr Nutrition BACKGROUND: A recent systematic review, which used the GRADE methodology, concluded that there is strong evidence for two gene-diet associations related to omega-3 and plasma triglyceride (TG) responses. Systematic reviews can be used to inform the development of clinical practice guidelines (CPGs). OBJECTIVE: To provide guidance for clinical practice related to genetic testing for evaluating responsiveness to dietary/supplemental omega-3s and their impact on plasma lipids/lipoproteins/apolipoproteins. DESIGN: Using the results of the abovementioned systematic review, the first CPGs in nutrigenetics were developed using the established GRADE methodology and AGREE II approach. RESULTS: Three clinical practice recommendations were developed. Most gene-diet associations identified in the literature lack adequate scientific and clinical validity to warrant consideration for implementing in a practice setting. However, two gene-diet associations with strong evidence (GRADE quality: moderate and high) can be considered for implementation into clinical practice in certain cases: male APOE-E4 carriers (rs429358, rs7412) and TG changes in response to the omega-3 fatty acids eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) as well as a 31-SNP nutrigenetic risk score and TG changes in response to EPA+DHA among adults with overweight/obesity. Ethical and regulatory implications must be considered when providing APOE nutrigenetic tests given the well-established link between APOE genetic variation and Alzheimer's Disease. CONCLUSION: Most of the evidence in this area is not ready for implementation into clinical practice primarily due to low scientific validity (low quality of evidence). However, the first CPGs in nutrigenetics have been developed for two nutrigenetic associations with strong scientific validity, related to dietary/supplemental omega-3 and TG responses. Frontiers Media S.A. 2022-02-14 /pmc/articles/PMC8883048/ /pubmed/35237638 http://dx.doi.org/10.3389/fnut.2021.768474 Text en Copyright © 2022 Keathley, Garneau, Marcil, Mutch, Robitaille, Rudkowska, Sofian, Desroches and Vohl. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Nutrition Keathley, Justine Garneau, Véronique Marcil, Valérie Mutch, David M. Robitaille, Julie Rudkowska, Iwona Sofian, Gabriela Desroches, Sophie Vohl, Marie-Claude Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids |
title | Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids |
title_full | Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids |
title_fullStr | Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids |
title_full_unstemmed | Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids |
title_short | Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids |
title_sort | clinical practice guidelines using grade and agree ii for the impact of genetic variants on plasma lipid/lipoprotein/apolipoprotein responsiveness to omega-3 fatty acids |
topic | Nutrition |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883048/ https://www.ncbi.nlm.nih.gov/pubmed/35237638 http://dx.doi.org/10.3389/fnut.2021.768474 |
work_keys_str_mv | AT keathleyjustine clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids AT garneauveronique clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids AT marcilvalerie clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids AT mutchdavidm clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids AT robitaillejulie clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids AT rudkowskaiwona clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids AT sofiangabriela clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids AT desrochessophie clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids AT vohlmarieclaude clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids |